AstraZeneca's TAGRISSO Shows Unprecedented 8-Year Survival in Early-Stage Lung Cancer
Event summary
- AstraZeneca's TAGRISSO demonstrated a 47% reduction in the risk of death compared to placebo in early-stage EGFR-mutated lung cancer patients at eight years.
- 74% of patients treated with TAGRISSO were alive at eight years versus 58% with placebo in the primary population (Stages II-IIIA).
- Results were presented at the IASLC 2026 World Conference on Lung Cancer and published in the Journal of Thoracic Oncology.
- Real-world evidence reinforced the importance of completing the full three-year treatment course with TAGRISSO.
The big picture
AstraZeneca's TAGRISSO continues to redefine the standard of care for early-stage EGFR-mutated lung cancer, reinforcing its position as a backbone therapy across multiple stages of the disease. The eight-year survival data underscores the importance of early intervention and EGFR testing at diagnosis, potentially expanding the market for targeted therapies in oncology. The results also highlight the growing trend of long-term follow-up studies in clinical trials to demonstrate sustained benefits of novel treatments.
What we're watching
- Market Positioning
- Whether AstraZeneca can sustain TAGRISSO's leadership in early-stage EGFR-mutated lung cancer treatment.
- Regulatory Approvals
- The pace at which regulatory bodies will approve TAGRISSO for broader adjuvant use based on these long-term data.
- Competitive Dynamics
- How competitors will respond to TAGRISSO's sustained survival benefits in the adjuvant setting.